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Amyotrophic Lateral Sclerosis (ALS) is being redefined as a distal axonopathy, in that many
molecular changes influencing motor neuron degeneration occur at the neuromuscular
junction (NMJ) at very early stages of the disease prior to symptom onset. A huge variety
of genetic and environmental causes have been associated with ALS, and interestingly,
although the cause of the disease can differ, both sporadic and familial forms of ALS show
a remarkable similarity in terms of disease progression and clinical manifestation. The
NMJ is a highly specialized synapse, allowing for controlled signaling between muscle
and nerve necessary for skeletal muscle function. In this review we will evaluate the
clinical, animal experimental and cellular/molecular evidence that supports the idea of ALS
as a distal axonopathy. We will discuss the early molecular mechanisms that occur at the
NMJ, which alter the functional abilities of the NMJ. Specifically, we focus on the role of
axon guidance molecules on the stability of the cytoskeleton and how these molecules
may directly influence the cells of the NMJ in a way that may initiate or facilitate the
dismantling of the neuromuscular synapse in the presymptomatic stages of ALS.
Keywords: Amyotrophic Lateral Sclerosis, distal axonopathy, axon guidance molecules, neuromuscular junction,
motor neuron, skeletal muscle, terminal Schwann cell
INTRODUCTION
Amyotrophic Lateral Sclerosis (ALS), first described in the liter-
ature 150 years ago by French neurologist Jean-Martin Charcot,
is a highly debilitating disease caused by progressive degeneration
of upper and lower motor neurons. Denervated muscles weaken
and atrophy, and death usually occurs due to respiratory failure.
ALS is an aggressive disease, with many patients dying within 3–5
years of diagnosis. Ninety percent of cases are considered spo-
radic (sALS), with varied environmental and/or genetic factors
influencing the pathophysiology. The discovery of a direct genetic
cause for ALS came in the early 1990s in the form of mutations
in the superoxide dismutase-1 gene (SOD1; Rosen et al., 1993),
which account for approximately 20% of familial ALS (fALS)
cases. To date, over 150 different mutations in SOD1 have been
linked with the disease, some causing a long clinical course (e.g.,
H46R) while others trigger an exceptionally aggressive form of
the disease (e.g., A4V; Redler and Dokholyan, 2012). Mutations
in other genes (alsin, senataxin, angiogenin, profilin, VAMP-
associated protein B, dynactin, TAR DNA-binding protein-43
[TDP-43] or fused in sarcoma [FUS]) account for another 10%
of fALS cases (Ludolph et al., 2012; Robberecht and Philips,
2013; Renton et al., 2014). A large portion of the remaining fALS
cases (∼50%) have now been attributed to an expansion of the
intronic hexanucleotide repeat sequence in C9ORF72 (Renton
et al., 2011).
It is becoming clearer that genetic factors may still play a role in
apparently sporadic disorders and this is illustrated by the discov-
ery of an increasing number of single nucleotide polymorphisms
(SNPs) linked to sALS across various populations and ethnici-
ties across the world (Laaksovirta et al., 2010; Shatunov et al.,
2010; Fogh et al., 2014). Various SNPs in chromosome 9 (which
also contains the C9ORF72 sequence connected to the majority of
fALS cases, see above) associate with the haplotype for frontotem-
poral dementia, supporting the idea of shared genetic causes for
ALS and other neurodegenerative disorders (Laaksovirta et al.,
2010; Shatunov et al., 2010). Overlap between particular path-
ways linked to ALS and Parkinson’s disease pathophysiology had
previously been identified by Lesnick and colleagues, who found
that SNPs in certain genes within the axon guidance pathways
in PD associated with ALS susceptibility, survival and age of
disease onset (Lesnick et al., 2008). Recently SNPs in chromo-
some 17 were identified via the largest association study to date
based on over 13,000 individuals from around the world, the lead
SNPs being localized in a gene related to Wallerian degeneration,
a mechanism that shares morphological features to the axonal
dying back process in ALS (Fogh et al., 2014).
In terms of the environmental aspects linked to sporadic ALS
pathophysiology an interesting cluster of sALS has been found
among (retired) American football or Italian soccer players (Chiò
et al., 2005, 2009; Lehman et al., 2012), and is thought not to
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be due to physical exercise per se, but rather a result of head
injury inherent to the sport itself. Ingestion of cyanobacteria-
contaminated bat meat or cycad seed derivatives was linked with
an ALS-like phenotype in inhabitants of the island of Guam and
was eventually shown to be caused by neurotoxins produced by
the cyanobacteria (Tabata et al., 2008; Bradley et al., 2013; De
Munck et al., 2013). A comparable clustering of sALS cases in
Gulf war veterans was attributed to the inhalation of desert dust
containing traces of cyanobacteria (Cox et al., 2009). Prior viral
infections (e.g., HIV) have also been linked to an increased risk of
an already susceptible individual to developing a neurodegenera-
tive disease, including ALS (Zhou et al., 2012; Alfahad and Nath,
2013). Other environmental causes, such as exposure to heavy
metals, pesticides, or lifestyle differences have been put forward,
but require further analysis to convincingly support a causal link
to sALS (Weisskopf et al., 2009; Trojsi et al., 2013).
Due to the wide variety of genes and mutations now identified
for fALS and the discovery of other (de novo) genetic and/or var-
ied environmental factors influencing sALS pathogenesis, it has
become clear that ALS has a highly varied etiology, which ulti-
mately converges to produce similar clinical symptoms. Care is
currently based on symptomatic treatment as there is no effective
disease-modifying therapy (reviewed in Phukan and Hardiman,
2009). The only approved medical treatment is Riluzole, a presy-
naptic glutamate release inhibitor, which merely extends life by
3–5 months (Miller et al., 2012). Nutritional management with
the aid of parenteral tubing can prevent excessive weight loss and
dehydration and may improve quality of life, but has marginal
survival benefits (Forbes et al., 2004). However, respiratory man-
agement by non-invasive ventilation has improved survival, albeit
in a subset of patients (Bourke et al., 2006).
In this review we will evaluate the clinical, animal experimen-
tal and cellular/molecular evidence that supports the idea of ALS
as a distal axonopathy, which proposes that pathological changes
occur at the neuromuscular junction (NMJ) prior to motor neu-
ron degeneration and onset of clinical symptoms. In addition,
we will discuss the early molecular mechanisms occurring at the
NMJ that may be inducing a loss in synaptic integrity by alter-
ing the stability of the distal cytoskeleton in the presymptomatic
phase of the disease, initiating a cascade of events that instigate
the distal axonopathy phenotype. We will specifically focus on
the role of axon guidance molecules in dismantling the NMJ,
emphasizing on their capacity to influence the stability of the dis-
tal cytoskeleton of the motor neuron during the presymptomatic
stages of ALS.
EARLY CLINICAL MANIFESTATIONS OF ALS
Clinical assessment of neuromuscular performance in ALS
patients has been the focus of many studies over the last decades
(Dengler et al., 1990; Killian et al., 1994; Schmied et al., 1999;
Fischer et al., 2004; Noto et al., 2011). Electrophysiological
changes are one of the first measurable alterations to occur and
form a large part of the tests used to diagnose ALS in humans; the
(modified) El Escorial criteria (De Carvalho et al., 2008) alongside
the Awaji criteria (Okita et al., 2011) provide electrophysiolog-
ical data, and this, combined with the ALS functional-rating
scale (Cedarbaum and Stambler, 1997) provides a more definitive
diagnosis. Nerve conduction measurements such as Muscle Fiber
Conduction Velocity (MFCV) can be 89% effective at predicting
the development of ALS in patients who already show denerva-
tion in muscle biopsies but do not yet conform to the other ALS
diagnostic tests mentioned above (Blijham et al., 2007). Altered
axon excitability in ALS patients has been observed to occur in
a distal to proximal fashion (Kanai et al., 2006; Nakata et al.,
2006; Vucic and Kiernan, 2006). In vivo data from animal stud-
ies indicates an increase in electrical excitability of hypoglossal
motor neurons can occur as early as 4 days after birth in the
G93A-hSOD1 ALS mouse (Van Zundert et al., 2008). Changes
in fasciculation potentials has been recently shown to precede
and anticipate NMJ instability and reinnervation, and is consis-
tent with a very early phase of increased axonal excitability (de
Carvalho and Swash, 2013). Axonal alterations are not only con-
fined to motor neurons as clinical evidence also suggests that
large-caliber myelinated fibers undergo axonal loss to produce
sensory abnormalities in some patients (Hammad et al., 2007).
THEORIES ON THE CAUSE(S) OF sALS
Over the last decades, many studies have identified potential
causes for sALS, some of which include excitotoxicity, astroglia,
and/or microglia dysfunction, oxidative stress and mitochondrial
dysfunction, endoplasmic reticulum stress, defects in RNA pro-
cessing, growth factor abnormalities, defects in axonal transport,
metabolic alterations and accumulation of protein aggregates
(reviewed in Robberecht and Philips, 2013). However, no research
has pointed toward a common pathway to collate these various
hypotheses, making it almost impossible to create an effective
neuroprotective therapy, as individual treatments for each of these
potential causes inevitably “ignores” the other factors involved
in the disease. Combinatorial treatments are a potential solution,
yet, the question still remains which causes do you target if there
is no direct knowledge about when these different biological dys-
functions occur over the course of the disease? Ideally, a therapy
should target the initial and early changes common to all forms of
ALS. Thus, the quest continues to unify the early biological causes
of ALS and determine the key factors that initiate the disease.
Although ALS has traditionally been described as a disease of
the motor neuron cell body, several studies using mutant SOD1
mice have illustrated the non-cell-autonomous pathogenic nature
of the disease. For a comprehensive review on glial-neuronal
interactions contributing to ALS, see Valori et al. (2014). The
well-studied G93A-hSOD1 ALS mouse, which models a subset
of the inherited disease based on mutations in the superoxide
dismutase-1 gene (SOD1), has been a vital tool in progressing our
understanding of ALS; this mouse exhibits behavioral symptom
onset at postnatal day 90 (P90) and death by P120-140 caused by
a gain-of-function toxicity mediated by themutant SOD1 enzyme
(Gurney et al., 1994). Mutant SOD1-related damage (i.e., oxida-
tive stress) in motor neurons is necessary in determining the
onset of disease initiation, whereas limiting G93A-hSOD1 expres-
sion tomicroglia and/or astrocytes accelerates disease progression
without affecting the onset (Boillée et al., 2006; Yamanaka et al.,
2008a,b). On the other hand, accumulation of or limiting the
expression of a dismutase active mutant SOD1 to Schwann cells
delays disease onset (Lobsiger et al., 2009; Turner et al., 2010).
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These studies demonstrate that various cells can have differing
functions (destructive or supportive) in terms of certain molec-
ular features of the disease but work in parallel to produce
the typical ALS pathophysiology. Another study focused on the
presymptomatic changes in non-neuronal cells and showed that
an increase in GFAP expression, indicative of activated astro-
cytes, is detected in the lumber spinal cord of ALS mice as early
as 25 days of age (Keller et al., 2009). With this in mind, it is
possible that early alterations in the astrocyte-motor neuron rela-
tionship create a vulnerable environment for the neuronal cell
body which may ultimately affect the survival of the motor neu-
ron (reviewed in Rafalowska et al., 2010; Phatnani et al., 2013).
Degenerative changes may also be occurring in oligodendrocytes:
a loss of oligodendrocytes in both ALS patients and presymp-
tomatic ALS mice has been described, and newly differentiated
oligodendrocytes that form to compensate for this loss have a
reduced expression of monocarboxylate transporter 1 (MCT-1)
rendering them dysfunctional in terms of the metabolic sup-
port they provide for motor neurons (Lee et al., 2012; Philips
et al., 2013). MCT-1 is expressed in neurons and other glial
cells, but it is the oligodendrocyte derived MCT-1 that pro-
vides metabolic support for axons as demonstrated by the axon
degeneration and subsequent motor neuron loss that occurs after
oligodendrocyte-specific knockdown of MCT-1 (Lee et al., 2012).
Thus, oligodendrocytes, too, play a role in motor neuron survival
and as such are important players in ALS-related motor neuron
degeneration.
In recent years, the “dying-back” hypothesis has obtained
much attention in the context of ALS pathophysiology. According
to this hypothesis, motor neurons and nerve terminals show
pathological changes prior to motor neuron degeneration and the
onset of clinical symptoms. Specifically, it proposes that ALS is a
distal axonopathy, whereby changes first occur distally at the NMJ
itself and progress proximally toward the cell body. Interestingly,
evidence of distal axonopathy has been found in other neurode-
generative diseases like Alzheimer’s disease or Parkinson’s disease,
where axonal defects occur prior to cell death and the loss of
axonal function correlates strongly with the onset of functional
decline (Selkoe, 2002; Dauer and Przedborski, 2003; Arendt,
2009).
Using mutant SOD1 ALS mouse models, several seminal
papers have provided experimental evidence for ALS as a dis-
tal axonopathy. Neuromuscular synapses differ in terms of their
anatomical plasticity and vulnerability to denervation, with the
most vulnerable (i.e., fast-fatigable; FF) synapses being lost early
in the disease process (Frey et al., 2000). Fischer and colleagues
observed that denervation of FF synapses at Type IIb/x muscle
fibers (at 47 days of age) and ventral root axon loss (at 80 days
of age) was occurring prior to loss of the cell body (at 100 days
of age) in the G93A-hSOD1 mouse (Fischer et al., 2004). Fischer
and colleagues also provided the first histological report of the
dying-back phenomenon occurring in humans in the form of a
patient with sALS who died unexpectedly: denervation and inner-
vation changes at the muscle were observed whereas pathological
changes in the motor neuron itself were not detected (Fischer
et al., 2004). This extends the electrophysiological observations
of Dengler and colleagues which were indicative of very early
changes in the function of distal peripheral nerves in patients
presenting with early muscle weakness (Dengler et al., 1990).
More recent evidence shows that presymptomatic changes in elec-
trophysiological parameters are predictive of clinical onset and
survival in the ALS mouse (Mancuso et al., 2011, 2014; Casas
et al., 2013). In addition, neuromuscular denervation appears to
occur independently to the activation of the cell death pathway
in motor neurons: ALS mice in which motor neuron death is
completely abolished still develop the disease although there is
a modest increase in survival due to a delay in muscle denerva-
tion and symptom onset (Kostic et al., 1997; Gould et al., 2006).
These studies support the idea that neuromuscular denervation
and symptommanifestation in ALS can occur regardless of motor
neuron survival, implicating that alterations elsewhere, e.g., in
skeletal muscle, muscle satellite cells or terminal Schwann cells
(TSCs) are able to influence axonal integrity, thus challenging the
“neurocentric” view of ALS (reviewed in Pansarasa et al., 2014).
Anatomically speaking, motor neurons synapsing on skeletal
muscles can be categorized into several functional classes: fast-
fatigable (FF), fast-fatigue resistant (FR) and slow (S). Skeletal
muscles are innervated by a characteristic composition of FF
(synapsing on Type IIb/x muscle fibers), FR (synapsing on Type
IIamuscle fibers) and S (synapsing on Type Imuscle fibers) motor
units, which provide the distinct force and twitch features that
define the functional properties of the individual muscle (Burke
et al., 1973). A motor unit is characterized by one motor neu-
ron and all the skeletal muscle fibers innervated by that axon.
FF motor units on Type IIb/x fibers are the most vulnerable and
the earliest to be lost in both human and rodent ALS (Dengler
et al., 1990; Frey et al., 2000; Atkin et al., 2005; Pun et al., 2006;
Saxena et al., 2009). Over the course of the disease, the preferential
denervation of Type IIb/x muscle fibers progressively leads to an
increase of Type I and IIa muscle fibers due to activity-dependent
conversion of the muscle fibers and collateral sprouting of surviv-
ing motor units (Hegedus et al., 2007, 2008; Gordon et al., 2010).
Fibers that remain denervated atrophy, and it is this constant
ebb-and-flow of denervation and reinnervation by reduced-force
capacity motor neurons that gives ALS its characteristic feature of
muscle weakness.
Interestingly, the selective vulnerability of FF synapses also
occurs in aged or induced-paralysis paradigms and coincides
with a lack of anatomical plasticity (Frey et al., 2000; Valdez
et al., 2012). On the other hand, slow type synapses, which are
more resistant to ALS and are the last to be affected, are capable
of stimulus-induced sprouting (Frey et al., 2000). This is con-
sistent with the idea that individual motor pools contain two
distinct types of motor neurons: those which degenerate and
those which can reinnervate (Schaefer et al., 2005), indicative
of motor neuron-intrinsic factors playing a role in this appar-
ent selective vulnerability. For example, preferential denervation
of FF motor units occurs in mice lacking wild-type SOD1 illus-
trating that these synapses are especially vulnerable to oxidative
injury (Fischer et al., 2011, 2012). Vulnerable motor neurons
are also more prone to endoplasmic reticulum stress, with an
unfolded protein response occurring at least 4 weeks prior to the
earliest denervation (Saxena et al., 2009). The extra-ocular mus-
cle remains largely innervated even in the terminal stages of the
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disease (Tjust et al., 2012), and a recent study using end-stage
ALS patient material found significant decreases in synaptic pro-
tein levels at the NMJs of limb muscles compared to extra-ocular
muscles that could explain this phenomenon (Liu et al., 2014). In
addition, motor neurons that are resistant to degeneration express
higher levels of calcium buffering proteins which may allow them
to be more resistant against excitotoxic stimuli and may explain
the resistance of the oculomotor and Onuf ’s nucleus to degen-
eration in ALS (Obál et al., 2006). Interestingly, pharmacological
modulation of calcium at the NMJ using calpain inhibitors has
been shown to protect the distal cytoskeleton from degradation
in cases of autoimmune peripheral neuropathies (O’Hanlon et al.,
2003), and support the idea of protecting the distal cytoskele-
ton as a therapeutic approach for preventing or delaying distal
axonopathies (see below for more discussion on the role of the
axonal cytoskeleton and ALS pathogenesis).
Mitochondrial (dys)function has also been linked to several
severe neurodegenerative diseases, ALS included (Filosto et al.,
2011; Narendra and Youle, 2012). In spinal motor neurons, mis-
folded mutant SOD1 protein preferentially binds to mitochon-
drial membranes (Vande Velde et al., 2008) and accumulation of
SOD1 mutations in mitochondria leads to organelle dysfunction,
oxidative stress and subsequent defects in neuronal physiology
(Liu et al., 2004; Deng et al., 2006). Interestingly, clustering of
mitochondria and mutant SOD1 in G93A-hSOD1 rats into dis-
crete domains within the motor neuron creates dysfunctional
regions along the axon which can lead to progressive axonopa-
thy (Sotelo-Silveira et al., 2009). In addition, overexpression
of mutant SOD1 in the intermembrane space of mitochondria
results in phenotypic features similar to ALS such as weight loss,
muscle weakness and motor impairment, but with no evidence of
muscle denervation (Igoudjil et al., 2011). Defects in mitochon-
drial DNA in human skeletal muscle have recently been observed
in both sporadic and familial forms of ALS (Artuso et al., 2013)
illustrating that it is not only dysfunction in motor neuron
mitochondria that can affect the disease process. Enhancing the
calcium buffering capacity of mitochondria in mutant SOD1 ALS
mice suppressed motor neuron death over the course of the dis-
ease, but did not ameliorate muscle denervation, motor axon
degeneration, disease progression or survival (Parone et al., 2013).
Recently, abnormal mitochondrial dynamics in skeletal muscle
of presymptomatic G93A-hSOD1 mice was discovered to directly
relate to muscle dysfunction (a feature which occurs early in dis-
ease progression) and therefore may be actively promoting ALS
progression (Luo et al., 2013). Thus, given that mitochondrial
dysfunction appears in many neurodegenerative diseases and is
not restricted to the vulnerable subpopulation of cells affected
by the disease, it is unlikely that they are primary contributors
in initiating the disease process; instead, defects in mitochondrial
physiology may play a role in amplifying the pathogenic process
(reviewed in Dupuis, 2014).
Defective RNA processing is emerging as a common feature
of many neurodegenerative diseases (Belzil et al., 2013). Several
lines of evidence illustrate how aberrant RNA processing due to
changes in TDP-43, FUS, and/or C9ORF72 may directly play a
role in the pathogenesis of both fALS and sALS (Droppelmann
et al., 2014; Raman et al., 2014). Mutations in the TDP-43,
FUS and C9ORF72 genes have been shown to alter normal
RNA processing which may, in turn, affect important protein
homeostasis causing (detrimental) changes in neuronal function
(Polymenidou et al., 2012; Ling et al., 2013). TDP-43 can be
actively transported within motor neurons to regulate axonal
growth by binding to and therefore modulating the fate of axonal
mRNA in the distal regions of the neuron (Fallini et al., 2012).
TDP-43 itself also plays a role in the transport of stress gran-
ules (vesicles containing mRNA transcripts) to the distal axon,
with ALS-linked mutations in TDP-43 causing impairment of
this transport (Alami et al., 2014). Interestingly, mutant TDP-43
results in altered RNA splicing behavior of TDP-43 targets such
as genes involved in synaptic transmission and function already
in the early stages of the disease (Arnold et al., 2013). In addition,
mislocalization, ormisregulation ofmRNA transcripts to or at the
distal compartment may itself impair synaptic function due to a
deficiency of important components at the nerve terminal (Mikl
et al., 2010). FUS and TDP-43 share similar roles in terms of RNA
processing, thus many of the effects mentioned above for TDP-43
can be mediated by FUS also (Lagier-Tourenne et al., 2012; Ling
et al., 2013; Deng et al., 2014). Of specific importance to the distal
axonopathy hypothesis of ALS, FUS has been linked with modu-
lating synaptic transmission at the NMJ by affecting the quantity
of neurotransmitter release (Machamer et al., 2014), which can
directly impact synaptic function.
Given that it has only recently been discovered as a genetic
cause for ALS, there is still much work to be done to decipher
the mechanism through which mutant C9ORF72 contributes to
ALS (Renton et al., 2011; Liu et al., 2014). A recent review high-
lights the possible mechanisms of action (Gendron et al., 2014),
but of most interest here is the idea that mutant C9ORF72 pro-
tein may sequester other RNA/DNA-binding proteins, such as
TDP-43, preventing their normal function, and thus may influ-
ence neuronal function indirectly by the processes regulated by
TDP-43 as described above.
TDP-43, FUS and C9ORF72 have also been linked with the
formation of insoluble, cytoplasmic aggregates characteristic of
degenerating motor neurons in ALS (Blokhuis et al., 2013) and
although the impact of protein aggregates in disease pathology is
still being determined, one could see these inclusions as physical
barriers preventing transport of vital cargos (mRNA transcripts
or protein) to the distal axon, and thus interfere with synaptic
function which in turn affects motor neuron health. In addi-
tion, mutant TDP-43 and FUS proteins may also contribute to
ALS pathology by affecting the biogenesis of microRNAs, which
are known to have an important role in motor neuron and NMJ
function (Williams et al., 2009; Kye and Gonçalves Ido, 2014).
Thus, defective RNA processing as mediated by changes in
TDP-43, FUS or C9ORF72 may influence synaptic function as a
trigger for motor neuron degeneration. Impairment of synaptic
function as an early pathological feature in the distal axonopathy
hypothesis of ALS will be further discussed below.
DISTINCTIVE AXONAL AND/OR SYNAPTIC FEATURES THAT
COULD INITIATE A MOTOR NEURON DISEASE PHENOTYPE
As described above mounting evidence suggests that the ear-
liest presymptomatic functional and pathological changes are
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occurring distally in axons and at the NMJ. These changes pre-
cede, and can be independent to, the loss of cell bodies or
alterations in other cell types already linked to the ALS disease
process (reviewed in Dupuis and Loeffler, 2009). The NMJ is a tri-
partite synapse, composed of the skeletal muscle fiber, the motor
neuron terminal and several TSCs (see Figure 1A), the latter being
important for maintaining synaptic integrity and influencing the
plasticity of the NMJ during development and disease (Son and
Thompson, 1995; Son et al., 1996; Auld and Robitaille, 2003).
Changes which induce pathological features at the NMJ can occur
due to intrinsic factors within the motor neuron as discussed
above, but recent evidence provides data to show that pathologi-
cal changes occurring in the skeletal muscle fiber itself and/or in
the TSCs can also lead to NMJ destruction prior to motor neuron
degeneration (De Winter et al., 2006; Jokic et al., 2006; Dupuis
et al., 2009; Gorlewicz et al., 2009).
One physiological aspect that is receiving much attention in
terms of an early sign for NMJ destruction is altered synap-
tic transmission. Recent evidence has demonstrated impaired
neuromuscular transmission in presymptomatic (4–6 weeks old)
ALS mice compared to age-matched controls (Rocha et al.,
2013). Impaired synaptic transmission and other electrophysi-
ological changes in electrical excitability or conduction velocity
disrupt the necessary interactions between the nerve terminal,
muscle fibers and TSCs required for appropriate postnatal for-
mation of the NMJ, which can lead to a delay in maturation of
the NMJ in presymptomatic animals (Blijham et al., 2007; Van
Zundert et al., 2008; Caillol et al., 2012). During development,
appropriate electrical activity is essential to get the correct dis-
tribution of the acetylcholine receptors (AChR) on the muscle
cell membrane for NMJ maturation at that location (Goldman
et al., 1988), thus one could speculate that the abnormal age-
appropriate activity seen at the NMJ of presymptomatic ALS
mice could alter the subcellular localization of the AChRs and
cause a destabilization of the affected NMJ. In fact, by experimen-
tally maintaining neuromuscular activity in partially denervated
muscles vulnerable motor units are able to survive longer over
the course of the disease (Gordon et al., 2010), illustrating the
importance of appropriate synaptic transmission in the health of
the NMJ.
Changes in electrophysiology can be indicative of a distur-
bance in appropriate cytoskeletal function, and recently an abun-
dance of studies have illustrated the importance of changes in the
distal cytoskeleton as a potential trigger for NMJ destruction in
ALS. The hallmarks of a distal axonopathy include mitochondrial
defects, aggregation of proteins and dysfunctional intracellu-
lar transport, and it has been suggested that a disturbance of
the distal cytoskeleton is a primary factor causing these hall-
mark features, and ultimately leads to the retraction of nerve
terminals from the NMJ (Soler-Martín et al., 2012). Axonal func-
tion heavily depends on a healthy cytoskeleton composed of
microfilaments and intermediate filaments (predominantly for
structural support) and microtubules (for intracellular trans-
port). Aggregates or abnormalities in neurofilaments (a sub-
class of intermediate filaments found in neurons) have been
directly linked to the ALS phenotype (Williamson et al., 1998;
Lalonde and Strazielle, 2003) and pharmacological stabilization
of microtubules decreases motor neuron death, and improves
life expectancy in ALS mice (Fanara et al., 2007), illustrating
the importance of the cytoskeleton in the ALS disease pro-
cess. Mutations in the profilin gene, an important mediator of
actin dynamics, has recently been found to account for a small
portion of inherited ALS cases (Wu et al., 2012) further link-
ing defects in the cytoskeleton as a feature of ALS. Additional
molecular changes occurring at the NMJ itself, whether orig-
inating from the muscle fiber, the TSCs or the motor nerve
terminal can be capable of influencing the stability of the
synapse during the course of ALS. These will be discussed
below, specifically focusing on how inducers of instability or
protectors of NMJ integrity are involved in a delicate bal-
ance to maintain the appropriate structure and function of
the NMJ.
MOLECULAR MECHANISMS THAT GOVERN DISTAL AXON
AND NMJ STABILITY AND/OR INSTABILITY
NEUROTROPHIC FACTORS
Over the last decades, a large body of evidence has supported
the administration of neurotrophic factors (such as glial cell
line-derived neurotrophic factor [GDNF], insulin-like-growth
factor [IGF-1], ciliary neurotrophic factor [CNTF] and vascular
endothelial growth factor [VEGF]) to ameliorate the ALS dis-
ease process, but with limited success in terms of a clinical use
for this approach (Henriques et al., 2010). However, the expres-
sion of most of these trophic factors show a remarkable decline
over the course of the disease (reviewed in Krakora et al., 2012)
suggesting that diminished neurotrophic support is contributing
to the disease. Interestingly, specifically targeting the muscle to
overexpress these neurotrophic factors (GDNF for example) has
led to the most efficient outcomes in terms of improved locomo-
tor performance and increase lifespan, compared to targeting the
motor neurons (via the spinal cord) themselves (Li et al., 2007;
Suzuki et al., 2008). Both studies reported an increase in the num-
ber of NMJs remaining innervated and the number of surviving
motor neurons inmid- to late-stages of the disease after intramus-
cular GDNF administration (Li et al., 2007; Suzuki et al., 2008).
Similarly, muscle-mediated IGF expression stabilized neuromus-
cular junction and enhanced motor neuron survival leading to
a delay in disease onset and a slowing of disease progression
(Kaspar et al., 2003; Dobrowolny et al., 2005). Intramuscular
administration of VEGF has also shown to preserve NMJs and
prolong survival (Azzouz et al., 2004; Zheng et al., 2007) and cur-
rently holds the most therapeutic potential in terms of a clinical
treatment for ameliorating ALS (Keifer et al., 2014). Although
CNTF has been shown to have survival promoting abilities for
vulnerablemotor neurons in ALSmousemodels (Pun et al., 2006)
and may have a role in compensatory sprouting in motor neu-
ron disease (Simon et al., 2010), due to its lack of positive effect
in clinical trials for ALS (adverse effects included an increase in
muscle weakness and a higher rate of weight loss in treated indi-
viduals; Bongioanni et al., 2004), its suitability as a treatment for
ALS definitely requires further assessment.
The mechanisms by which neurotrophic factors modify the
axonal cytoskeleton to stabilize the NMJ are not well under-
stood but several recent studies have tried to shed light on this
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FIGURE 1 | (A) A healthy neuromuscular junction (NMJ) is a tripartite
synapse composed of a motor neuron (MN) terminal synapsing onto a
muscle fiber. Terminal Schwann cells (TSCs) that envelop the junction have
a role in supporting and maintaining the motor neuron terminal. (B)
Potential endogenous compensatory effects that could counteract NMJ
instability in ALS. CD44 is upregulated by TSCs in ALS mice and is known
to encourage IGF-1 production to provide trophic support to damaged
muscle fibers. CD44 has also been found to colocalize with ErbB, and can
amplify the NRG1-ErbB pathway with two potential outcomes (1) indirectly
via paracrine stimulation of the NRG1-ErbB pathway in MN, which is
involved in synapse formation/maturation and/or (2) directly via NRG1-ErbB
pathway in TSCs, which is involved in survival and maintenance of TSC
(vital for correct synapse function). APP (in muscle) can be cleaved (by
α-secretase followed by γ-secretase) to form secreted-APP-α (sAPP-α),
which can bind CRMP2 (and maintain it in a non-phosphorylated,
neuroprotective state) resulting in stabilization of the neuronal cytoskeleton.
sAPP-α is also known to bind SEMA3A and prevent its repulsive effects on
the nerve terminal (presumably by preventing SEMA3A binding to NRP1,
which leaves CRMP2 in an unphosphorylated, neuroprotective state, thus
helping to stabilize the neuronal cytoskeleton). (C) Detrimental effects of
non-guidance and axon guidance molecules on NMJ stability in ALS.
Non-guidance molecules (in purple) such as galectin-1 (gal-1; secreted from
TSCs) and amyloid precursor protein (APP; expressed by damaged muscle
fibers) can both directly cause synapse degradation (see main text for
further detail). Axon guidance molecules (in green) like SEMA3A
(expressed by TSCs), NOGO-A (expressed by muscle fibers) and EPHA4
(expressed by motor neurons) are upregulated in ALS mice. SEMA3A and
NOGO-A can influence the stability of the neuronal cytoskeleton via
activation of the collapsing response mediator protein (CRMP)-pathway.
SEMA3A does this via interaction with neuropilin-1 (NRP1) on the plasma
membrane of MN, resulting in the phosphorylation of CRMP2. NOGO-A (in
muscle) interacts with its receptor, NgR (on MN), to activate the
CRMP4-RhoA kinase pathway. CRMP2 and CRMP4 can interact directly
with cytoskeletal proteins (microtubulin and actin respectively) to
negatively alter their dynamics. EPHA4 (expressed by MN) feeds into the
RhoA-kinase pathway, which also regulates cytoskeletal dynamics. (D)
Potential therapies that target specific molecular components of the NMJ
to improve NMJ stability in ALS. The administration of trophic factors (such
as VEGF, IGF-1, and GDNF) has been shown to have direct neuroprotective
effects and/or effects on TSC survival and maintenance (Krakora et al.,
2012). Administration of recombinant gal-1 (gal-1oxd; the oxidized form) is
neuroprotective; presumably through a mechanism that enhances
VEGF-signaling (gal-1oxd binds NRP1, which enhances binding of
co-receptor VEGFR2). Administration of β-secretase blockers has the
potential to enhance sAPP-α production (by enhancing the
non-amyloidogenic cleavage pathway). sAPP-α binds to unphosphorlyated
CRMP2 which may help maintain CRMP2 in an non-phosphorylated state
and thus aid in the stabilization of the neuronal cytoskeleton. Neutralization
strategies using antibodies directed toward NRP1 (Venkova et al., 2014) or
NOGO-A (Bros-Facer et al., 2014) have the ability to inhibit these signaling
pathways, probably by preventing phosphorylation of the appropriate
CRMPs, and thus enhancing neuronal cytoskeleton stabilization. Fasudil, a
RhoA-kinase inhibitor, can be administered to prevent EPHA4 function by
inhibiting the activation of downstream mediators that usually lead to the
destabilization of the neuronal cytoskeleton. The ideal treatment for ALS
would therefore combine the various interventions listed above to increase
the potential success of the therapeutic approach by enhancing the
beneficial pathways and inhibiting the destructive pathways respectively.
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question. During development, the neuronal growth cone directs
the developing axon by translating environmental guidance cues
into cytoskeletal rearrangements. New evidence has revealed that
upon VEGF stimulation, the actin cytoskeleton in the growth
cone undergoes immediate and fast rearrangement that enables
increased motion (Olbrich et al., 2013). One could speculate that
a similar event is occurring at the NMJ in ALS mice upon trophic
factor administration; the cytoskeleton of the motor neuron ter-
minal is modified to a highly active state by the presence of the
trophic factor at the NMJ enabling it to remain stable in an oth-
erwise destructive environment. Supporting this idea is a recent
study whereby CNTF treatment in mice with motor neuron dis-
ease was shown to activate a pathway leading to microtubule
stabilization, allowing axon elongation andmaintenance (Selvaraj
et al., 2012).
Interestingly, overexpression of GNDF in muscle, but not in
glia, causes hyperinnervation of NMJs, resulting in the forma-
tion of multiple end-plates per muscle fiber (Nguyen et al., 1998;
Zwick et al., 2001) and leads to earlier regeneration (i.e., increased
axonal sprouting) following sciatic nerve crush (Magill et al.,
2010). Could muscle-mediated overexpression of neurotrophic
factors in a disease or injury paradigm improve the regenera-
tive outcome by also affecting the TSCs present at the NMJ?
Peripheral Schwann cells can be categorized into the myelinat-
ing variety (positioned along peripheral nerves) and the non-
myelinating variety (e.g., the TSCs of the NMJ), their iden-
tity being defined by a variety of signals during development
(Jessen and Mirsky, 2002). By acting via neurotrophic factor
receptors that remain expressed during adulthood in (terminal)
Schwann cells (Sondell et al., 1999; Hess et al., 2007; Garcia
et al., 2010), muscle-derived overexpression of neurotrophic fac-
tors can stimulate (terminal) Schwann cell migration (in the
case of GDNF; Iwase et al., 2005) and increase the number of
TSCs at the NMJ (in the case of neurotrophin-3, NT-3; Hess
et al., 2007). In addition to their maintenance role at the neuro-
muscular synapse, neurotrophic factors have also been shown to
modulate signaling between neurons and glial cells at the NMJ
during development (Todd et al., 2007). In this way, a dam-
aged or denervated neuromuscular synapse may benefit from the
increased influx of TSCs at and around the synapse (mediated
by muscle-mediated overexpression of trophic factors), whose
plastic responses in disease or injury models serve to guide
nerve sprouting, reinnervation and signaling at the neuromuscu-
lar synapse (Son et al., 1996; Tam and Gordon, 2003a; Sugiura
and Lin, 2011).
What these studies demonstrate is that maintaining trophic
factor expression at the NMJ helps to preserve the NMJ by mod-
ifying the cytoskeleton of the motor neuron, which translates to
a slowing down of disease progression with an improvement in
motor performance and life span. However, changes in other
molecular pathways are still present and these will also influ-
ence the stability of the NMJ. These changes can be roughly
divided in two categories: molecules that are involved in various
aspects of cell-cell signaling and/or cell adhesion (we refer to these
as “non-guidance molecules”) and molecules that are known
to govern axon-guidance and/or synapse formation (“guidance
molecules”).
NON-GUIDANCE MOLECULES
The cytosolic form of galectin-1 (gal-1) was first linked to the
pathophysiology of ALS as a component of axonal neurofilamen-
tous spheroids in sALS and fALS (Kato et al., 2001). Galectins
form a large family of proteins involved in mediating cell-cell
interactions, cell-matrix adhesion and transmembrane signaling
(Camby et al., 2006; Yang et al., 2008). Both gal-1 and gal-3 have
been associated with ALS, the latter as a candidate biomarker
for the disease (Gonzalez de Aguilar et al., 2008; Zhou et al.,
2010). In the terminal stages of ALS (at 120d in the G93A-
hSOD1 ALS mouse), an 11-fold increase in gal-3 was identified
in motor neurons compared to age-matched non-transgenic con-
trols (Ferraiuolo et al., 2007), but warrants further analysis to
understand its role. Gal-1 has been studied in more detail with
regards to its role in the disease which seems to be dependent on
its localization and oxidative state. A delicate equilibrium exists
between monomer and dimer formation, based on the oxida-
tive state of the protein, which in turn gives rise to the various
functions of gal-1 (Stowell et al., 2009). Cytosolic, non-oxidized
gal-1 is upregulated after injury in all TSCs where it is thought
to have a role in the pruning of damaged nerve endings after a
lesion (Plachta et al., 2007), but the timing of when gal-1 would
be upregulated in ALS is unknown. Based on the work of Plachta
et al. (2007) one could expect gal-1 to be first upregulated in the
TSCs of FF synapses in ALS as they are the first to shown signs of
(morphological) damage during disease progression (Frey et al.,
2000), potentially forming part of the molecular signature that
gives these synapses their vulnerability to damage. However, this
remains to be studied in detail.
In vitro evidence supports an early role for gal-1 in distal
axonopathy in that processes of cultured wild-type neurons are
affected first upon treatment with non-oxidized recombinant gal-
1, followed by the cell body (Plachta et al., 2007). Specifically
interesting in the context of ALS is the fact that disintegration of
the neuromuscular junction is delayed after sciatic nerve lesion in
mice lacking the gene for gal-1 (Plachta et al., 2007), supporting
the idea that gal-1 has a role in dismantling the NMJ. Remarkably
the oxidized, secreted form of gal-1 actually promotes axonal
regeneration (Horie and Kadoya, 2004) and when administered to
ALS mice in recombinant form, it improves motor activity, delays
disease onset and prolongs survival of treated animals (Chang-
Hong et al., 2005; Kato et al., 2005), highlighting its potential as
a therapeutic strategy to stabilize NMJs. The molecular mecha-
nisms by which the secreted form of galectin-1 promotes axonal
regeneration or stabilizes NMJs are still unknown, but a recent
study has identified secreted, oxidized gal-1 as a novel ligand for
neuropilin-1 (NRP-1), activating the VEGF-signaling pathway to
mediate migration and adhesion of endothelial cells (Hsieh et al.,
2008). NRP1 is an important component in the VEGF signaling
pathway, and in the ALS disease paradigm, treatment with VEGF
has been shown to stabilize NMJs, improve motor function and
prolong survival in ALS mice (Lambrechts et al., 2003; Azzouz
et al., 2004; Storkebaum et al., 2005; Zheng et al., 2007) via its
neuroprotective effects on motor neurons (Llado et al., 2013).
Thus, one could speculate that a mechanism whereby the VEGF
pathway is stimulated via oxidized gal-1 binding with NRP1 on
the motor neuron surface to activate the co-receptors necessary
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for VEGF-signaling, promotes NMJ stabilization with subsequent
beneficial effects on the ALS phenotype.
The transmembrane glycoprotein CD44 is a member of the
cell-adhesion molecule family of proteins important in extracel-
lular matrix function (reviewed in Goodison et al., 1999), and
during development of peripheral nerves it is expressed in glial
cells and has a role in maintaining neuron-Schwann cell inter-
actions (Sherman et al., 2000). However, it remains expressed
in TSCs at the NMJ (and other non-myelinating Schwann cells)
throughout adulthood, but greatly increases in expression in these
cells upon disease-related denervation in rat ALS skeletal mus-
cle (Gorlewicz et al., 2009). Interestingly, CD44-positive TSCs
are found in NMJs across all types of muscle fibers (Gorlewicz
et al., 2009), thus although this molecule influences glial plas-
ticity at the NMJ it is probably not a feature of the selective
vulnerability seen at the NMJs of FF motor neurons in ALS
(Frey et al., 2000). Instead, the enhanced expression of CD44
(or other cell-adhesion molecules) by TSCs may illustrate a com-
pensatory mechanism to facilitate TSC plasticity in response to
pathological denervation-reinnervation, and this could be hap-
pening already in the presymptomatic phases of the disease.
The study by Gorlewicz and colleagues showed that CD44 was
increased in TSCs in end-stage ALS mice compared to age-
matched wild-type controls (Gorlewicz et al., 2009) but evidence
exists to show that increased expression of other cell-adhesion
molecules (such as N-CAM) occurs in parallel with, and may
be a compensatory feature against, the early event of fast-twitch
muscle denervation (Gordon et al., 2009). During develop-
ment, N-CAM has an important role in mediating adhesion
between neurons, glial cells and muscle cells prior to synapto-
genesis (Rutishauser, 1985). Thus, an increase in N-CAM after
nerve injury may function to prime denervated skeletal mus-
cle for reinnervation (Covault and Sanes, 1985). In the context
of ALS, one can speculate that an increased expression of N-
CAM (or other cell adhesion molecules, such as CD44) may be
a compensatory reaction to the denervation that is occurring
in an effort to maintain the muscle fiber in a state suitable for
reinnervation.
Recently, an increase in colocalization between CD44 and
ErbB3 in the TSCs of ALS rodents was identified (Gorlewicz et al.,
2009). Members of the ErbB family are important receptors in
the neuregulin (NRG1) pathway which mediates neuromuscular
synapse formation by maintaining the postsynaptic specialization
in the muscle and thereby enhances synaptic transmission at the
NMJ (Trachtenberg and Thompson, 1997; Schmidt et al., 2011).
In addition, ErbB expression and the NRG1 pathway in (terminal)
Schwann cells is necessary for the proliferation, migration and
survival of these cells during development (Riethmacher et al.,
1997; Garratt et al., 2000;Wolpowitz et al., 2000). Given that TSCs
play an important role in NMJ plasticity and axonal sprouting
after injury and in disease paradigms (Tam and Gordon, 2003a,b;
Gordon et al., 2004), one can assume that by concentrating ErbB
receptors on the membrane of the TSCs as mediated by CD44
expression (Gorlewicz et al., 2009), the NRG1-ErbB pathway is
enhanced within TSCs and may boost their protective abilities
at the NMJ by potentially controlling TSC-derived neurotrophin
production (Garratt et al., 2000). Interestingly, mutations in the
ErbB4 gene leading to disruption of the NRG1-ErbB pathway has
been shown to cause a clinical subset of ALS (Takahashi et al.,
2013), supporting the importance of this pathway as a protective
mechanism against the disease.
Additionally, CD44 has also been found to be upregulated in
astrocytes and microglia in the spinal cord of 12 week old ALS
mice, the time at which the clinical phase of the disease begins,
and increases over time (Matsumoto et al., 2012). In injured
spinal cord, chondroitin sulfate proteoglycans in the extracellular
matrix can act via CD44 to promote the production of IGF-1 by
astrocytes andmicroglial cells (Rolls et al., 2008). Could the extra-
cellular matrix at the NMJ in muscle be using CD44 in TSCs to
stimulate IGF-1 production, a trophic factor which, when exoge-
nously administered, is known to promote NMJ stability and
improve the ALS phenotype (Kaspar et al., 2003; Dobrowolny
et al., 2005)?
The amyloid precursor protein (APP), a membrane protein
with the ability to regulate synapse formation and repair (Priller
et al., 2006; Nalivaeva and Turner, 2013; Octave et al., 2013)
has been widely studied for its role in Alzheimer’s disease, but
its role in other neurodegenerative diseases such as ALS con-
tinue to be discovered (Muresan et al., 2014). During (post-natal)
development of the NMJ, APP expressed by the skeletal muscle
is involved polyneural synapse elimination to create a mono-
innervated synapse through interaction with post-synaptic com-
ponents involved in junction formation (Akaaboune et al., 2000;
Choi et al., 2013). The extracellular fragment of APP has been
shown to act via the Death Receptor 6 (DR6) apoptotic pathway
to regulate axonal behavior during development, and the acti-
vation of this pathway due to loss of trophic support has been
linked to peripheral nerve degeneration after axonal damage in
adulthood (Nikolaev et al., 2009). Following post-natal matura-
tion of the NMJs, APP is downregulated in adult skeletal muscle
(Akaaboune et al., 2000). However, APP is found to be elevated in
muscle prior to the appearance of clinical symptoms in both ALS
mice and in human patients (Koistinen et al., 2006) and in motor
neurons in presymptomatic ALS mice (Ferraiuolo et al., 2007).
Its role in ALS was further defined by Bryson and colleagues who
showed that APP expression at the muscle is triggered by dener-
vation and, notably, is specific to Type IIb fibers (Bryson et al.,
2012), these fibers being the first to become denervated in ALS
(Frey et al., 2000). In addition, genetic ablation of APP improves
innervation, motor function and motor neuron survival in ALS
mice, further emphasizing its importance in the pathophysiology
of ALS (Bryson et al., 2012). Importantly, removal of APP did
not extend survival in the ALS mice, suggesting that the detri-
mental effects of APP contribute to the onset and early phases
of the disease (Bryson et al., 2012). Given the fact that a lack
of APP can enhance the number of functional synapses in vitro
(Priller et al., 2006), presymptomatic expression of APP (in the
muscle or the neuron) may initiate synaptic apoptosis at the NMJ
in ALS (perhaps due to reactivation of its role in the elimination
of multi-innervated synapse during development; (Akaaboune
et al., 2000). In conjunction with other destructive factors (dis-
cussed below), normal synaptic function is compromised, which
leads to further denervation of the synapse and the progressive
neuronal degeneration typical of the disease.
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GUIDANCE MOLECULES
Various axon guidance cues, with important roles during neu-
ronal development, are now being linked to the pathophysiology
of ALS, and more importantly, to the presymptomatic stages of
the disease (Schmidt et al., 2009). These include semaphorin3A,
EphrinA4 and NOGO-A. The secreted repulsive axon guidance
cue semaphorin3A (SEMA3A), is selectively upregulated in TSCs
in presymptomatic ALS mice, specifically at the NMJs on Type
IIb muscle fiber (De Winter et al., 2006). Further evidence
implicates the SEMA3A signaling pathway in ALS. First, ALS-
mice with motor neuron specific knockout of the receptor for
SEMA3A, neuropilin-1 (NRP1), display improved motor func-
tion (Moloney et al., 2012). Second, treatment of ALS-mice with a
monoclonal antibody that interferes with SEMA3A-NRP1 signal-
ing prolonged survival and improved motor function (Venkova
et al., 2014). These improvements are thought to be due to
the disruption of signaling to the downstream effectors of the
SEMA3A signaling pathway, the collapsin response mediator
proteins (CRMPs), which are known to mediate various roles
during development and maturation, including neuronal migra-
tion, synapse formation, and synaptic plasticity by switching their
phosphorylation status (Yamashita and Goshima, 2012). Upon
SEMA3A binding to NRP1, CRMPs are phosphorylated and this
facilitates SEMA3A-mediated growth cone collapse by causing the
dismantling of cytoskeletal structures in vitro (Goshima et al.,
1995; Deo et al., 2004; Schmidt and Strittmatter, 2007; Hida et al.,
2012). In presymptomatic ALS mice, CRMP4a is upregulated in
a subset of lumbar motor neurons, and was shown to be directly
linked to motor neuron degeneration (Duplan et al., 2010), pre-
sumably through its ability to modulate the actin cytoskeleton
(Alabed et al., 2007). Specific population-associated mutations
within the CRMP4a gene have recently been found to cause
a shortening of survival in affected motor neurons by impair-
ing axonal growth (Blasco et al., 2013). With this in mind it is
plausible that the subpopulation of motor neurons that express
(mutant) CRMP4a correspond to the susceptible FF motor neu-
rons synapsing on Type IIb/x fibers, but this has yet to be
confirmed.
Interestingly, although intramuscular AAV-mediated overex-
pression of CRMP4a leads to a significant increase in denervation
and motor neuron death in WT mice, there were no such effects
after CRMP2 overexpression (Duplan et al., 2010), which may
point to differences in the way each CRMP exerts its effects on
the cytoskeleton. The effects of CRMP2 on the cytoskeleton seem
to be regulated by several mechanisms, most importantly by the
phosphorylation state of CRMP2 itself which leads to disrup-
tion of microtubule assembly (Gu and Ihara, 2000; Yoshimura
et al., 2005; Yamashita and Goshima, 2012). As phosphorylation
of CRMP2 is important in mediating CRMP2’s negative effects
on the cytoskeleton and is facilitated by SEMA3A binding (Deo
et al., 2004; Uchida et al., 2005; Hensley et al., 2011; Khanna et al.,
2012), overexpression of CRMP2 alone, especially in an uninjured
system where SEMA3A is not present, may not result in adequate
phosphorylation of CRMP2 to allow for cytoskeletal abnormal-
ities and subsequent motor neuron degeneration as mediated
by CRMP4a overexpression (Duplan et al., 2010). In addition,
abnormal phosphorylation of CRMP2 has been identified as a
characteristic feature of Alzheimer’s disease (Williamson et al.,
2011) and further work is focusing on its role in other neurode-
generative disorders in terms of cytoskeletal alterations (Hensley
et al., 2011). In its unphosphorylated state, CRMP2 can actively
stimulate neurite outgrowth (Yoshimura et al., 2005) thus by
inhibiting SEMA3A signaling one could promote the accumu-
lation of unphosphorylated CRMP2 in an effort to create an
environment at the NMJ that is more permissible to maintaining
the synapse in a healthy state. Studies focusing on the (pharmaco-
logical) stabilization of CRMP2 in its unphosphorylated state are
also promising for their potential as treatments for ALS as well
as other neurodegenerative disorders (Hensley et al., 2010, 2011;
Khanna et al., 2012).
In addition, protein-protein interactions that modulate
CRMP2 function have been identified. Targeted disruption of ret-
rograde transport is known to result in neuromuscular changes
consistent with progressive motor neuron diseases (LaMonte
et al., 2002; Puls et al., 2003) and SOD1-mutant ALS mice display
impaired axonal transport months prior to disease onset which
could indicate that decreased transport is correlated with develop-
ment of motor neuron disease (Williamson and Cleveland, 1999).
Active transport along microtubules requires kinesin and dynein
and CRMP2 has been found to bind dynein and negatively regu-
late dynein-mediated retrograde transport (Arimura et al., 2009;
Rahajeng et al., 2010). In this scenario it seems that CRMP2 acts
as a linking protein between the molecular motors and the micro-
tubule cytoskeleton, but it is not clear from these studies whether
this function is dependent on CRMP2’s phosphorylation state.
CRMP2 function can also be directly modulated by other mem-
bers of the CRMP family. Unphosphorylated CRMP2 promotes
axonal outgrowth by assisting tubulin assembly (Fukata et al.,
2002; Yoshimura et al., 2005), but this function can be inhibited
by the presence of CRMP5 (Brot et al., 2010) providing another
potential point at which CRMP2 function can be manipulated by
targeted therapeutic approaches against CRMP5 function.
Additionally, CRMP2 has been found to be a putative bind-
ing partner for sAPP-α (Pawlik et al., 2007), a soluble, secreted
ectodomain isoform produced by α- and γ-secretase cleavage of
the main neuronal APP through the non-amyloidogenic path-
way. In the amyloidogenic pathway APP is sequentially cleaved by
β-secretase followed by γ-secretase to produce the amyloid-beta
product, well known for its involvement in neuronal degeneration
in Alzheimer’s disease (O’Brien and Wong, 2011). Interestingly,
sAPP-α is neuroprotective, enhances neurite elongation andmod-
ulates synaptic plasticity (Turner et al., 2003), so perhaps the
interaction between sAPP-α and CRMP2 strengthens their neu-
roprotective effects. Further supporting this idea is the finding
that sAPP-α itself can directly interact with SEMA3A and prevent
SEMA3A-induced growth cone collapse in vitro (Magdesian et al.,
2011). Therapeutic approaches that would enhance the cleavage
of APP to sAPP-α (e.g., by inhibiting β-secretase function) could
effectively “kill two birds with one stone”: APP bioavailability
decreases and the SEMA3A signaling pathway is inhibited by the
presence of sAPP-α. In this way modulating β-secretase function
and APP bioavailability could potentially have a positive effect
on the stability of the cytoskeleton at the NMJ and has already
been shown to delay the onset of neuronal degeneration in ALS
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(Rabinovich-Toidman et al., 2012). However, one has to proceed
with caution as β-secretase is required for NRG1-mediated myeli-
nation of the peripheral nerve (Hu et al., 2006;Willem et al., 2006)
and therefore inhibition may alter the beneficial effects of NRG1
signaling in Schwann cells (see above for details regarding the
NRG1 pathway in ALS). One way around this may be to enhance
the dimerization of APP itself with small molecule compounds,
which alters APP conformation and influences the ratio of cleav-
age by α- and β-secretase to result in significantly higher levels of
sAPP-α (Libeu et al., 2012).
SEMA3A expression may also be a part of the myogenic pro-
gram necessary for muscle regeneration after muscle injury. It has
not yet been studied in the context of ALS, but given that satellite
cells become activated after muscle injury or denervation (Seale
and Rudnicki, 2000) and begin to express and secrete SEMA3A
(Sato et al., 2013) it is possible that, upon disease-related denerva-
tion, satellite cells in an ALS muscle would also begin to produce
SEMA3A. An array of growth factors modulate the expression
of SEMA3A (Tatsumi et al., 2009; Do et al., 2011) giving rise to
the idea that SEMA3A, expressed by satellite cells, may serve a
beneficial role in terms of skeletal muscle regeneration in that it
delays neuronal sprouting and re-attachment of nerve terminals
until damaged muscle fibers have been restored. The myogenic
pathway is active in presymptomatic ALS mice, but as the dis-
ease progresses, the function of satellite cells becomes impaired
(Pradat et al., 2011; Manzano et al., 2013) and levels of myogenic
proteins decrease even though RNA levels remain high (Manzano
et al., 2011). If the myogenic process is unable to maintain muscle
regeneration, muscle fibers are not restored and SEMA3A con-
tinues in its role in delaying re-attachment of terminals. This, in
combination with other destructive factors occurring at the NMJ,
could result in a “snowball” effect of NMJ degeneration.
EphrinA4 (EPHA4), a receptor tyrosine kinase, is a mem-
ber of the ephrin family known to have well-established func-
tions in axonal repulsion during neuronal development. During
adulthood EPHA4 can regulate synapse formation and plastic-
ity (Klein, 2009). In human ALS patients, low levels of EPHA4
have been associated with later disease onset and/or a slower
disease progression, providing a site for potential therapeu-
tic intervention (Van Hoecke et al., 2012). Furthermore, large
motor neurons, which are more vulnerable to degeneration,
were found to express higher quantities of EPHA4 mRNA in
presymptomatic ALS providing additional evidence for the dif-
ferential vulnerability of motor neurons in ALS (Van Hoecke
et al., 2012). Inhibition of EPHA4 genetic ablation, was also
shown to rescue motor neuron degeneration in ALS mice and
increase the number of NMJs being re-innervated after sciatic
nerve axotomy (Van Hoecke et al., 2012). These data point to
EPHA4 being a vital member of the molecular repertoire that
causes a motor neuron to be more susceptible to degeneration.
Interestingly, inhibition of EPHA4 also rescues other motor neu-
ron deficits in TDP-43 or SMN1-induced axonopathies which
may indicate that the EPHA4 is independent to how degeneration
occurs but instead maybe be a “generic determinant of vulner-
ability of neurons to degeneration” (Van Hoecke et al., 2012).
Pharmacological studies have identified the potential of fasudil
(an inhibitor of rho-kinase function, a downstream mediator of
EphrinA signaling) for improving motor function after stroke
(Lemmens et al., 2013) and limits motor neuron loss in ALS mice
(Van Hoecke et al., 2012; Takata et al., 2013). As a results, a Phase
II open-label trial (ClinicalTrial.gov: NCT01935518) was initiated
in September 2013 to identify the efficacy of fasudil treatment in
slowing functional decline in ALS patients, with results expected
in 2015.
To date, NOGO-A has been the most promising in terms
of therapeutic potential in relation to NMJ destruction in ALS
pathophysiology. This myelin-derived protein is known to act
on the cytoskeleton to exert inhibitory effects on neurite out-
growth, and is a major factor in the failure of CNS axons to
regrow after injury (Pernet and Schwab, 2012). In vitro evidence
shows that stimulation of neuronal growth cones with NOGO-A
results in colocalization of CRMP4 and RhoA to mediate actin-
dependent cytoskeletal rearrangements (Alabed et al., 2007).
NOGO-A is highly expressed in skeletal muscle of presymp-
tomatic ALS rodents and in clinical defined ALS patients and may
even be a prognostic marker, its levels correlating with the sever-
ity of motor impairment as the disease progresses (Dupuis et al.,
2002; Jokic et al., 2005; Pradat et al., 2007). A clear link to NMJ
integrity was illustrated whereby genetic ablation of NOGO-A in
ALSmice reducedmuscle denervation and increased survival, and
overexpression of NOGO-A in muscle of wild-type mice destabi-
lized NMJs (Jokic et al., 2006). NMJ destabilization by NOGO-A
is consistent with the fact that NOGO-A signaling has been linked
to synaptic plasticity and stability in hippocampal neurons (Peng
et al., 2011) and in the adult cerebral cortex (Akbik et al., 2013).
A recent study has illustrated the potential of anti-NOGO-A anti-
bodies in significantly improving neuromuscular function even
when administered to ALS mice in the symptomatic stages of
the disease (Bros-Facer et al., 2014). Currently a Phase II trial is
underway using anti-NOGO-A antibodies (GSK; Ozanezumab)
in an effort to neutralize NOGO-A function in ALS patients
(ClinicalTrials.gov: NCT01753076), with primary results due in
May 2015.
CONCLUSION
Ultimately, ALS is a multifaceted disease with multiple modi-
fiers that enhance axon retraction and/or destabilize the NMJ
and therefore a more effective approach to designing therapeutic
interventions is to consider all (known) components that influ-
ence NMJ integrity (see Table 1 for an overview of molecules
discussed in this review). The interventions discussed above
(enhanced expression of neurotrophic factors, neutralization of
inhibitory axon guidance cues) individually do not prevent the
disease. Although disease onset is delayed by certain interven-
tions in the neurotrophic factor, “non-guidance” or “guidance”
molecule pathways, resulting in increased motor neuron sur-
vival and motor performance, the disease phenotype ultimately
manifests itself. Intrinsic pathways, including those mediated
by cell-adhesion molecules, are present to compensate for den-
ervation but ultimately fail to overcome the rate and level of
denervation (see Figure 1B). Combination therapies which aim
to inhibit the destructive features and enhance the compensatory
features could be a powerful way to halt the disease process in the
presymptomatic stage (see Figure 1D).
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As discussed, NMJ destruction may begin due to a combi-
nation of factors; vulnerable neurons display altered cytoskeletal
properties due to the effects of external guidance cues present in
the vicinity of the synapse (see Figure 1C). By combining several
therapeutic approaches that interfere with the effects of guid-
ance molecules specifically, one could create an environment that
allows for the NMJ to remain stable in the context of ALS (see
Figure 1D). By inhibiting EPHA4, the vulnerability of neurons
to degeneration could be reduced thus creating more resistant
motor neurons; by inhibiting SEMA3A secreted by TSCs, the
TSCs could continue to maintain the NMJ in an suitable state,
allowing appropriate neurotransmission to occur between the
motor neuron and muscle fibers whereby Type IIb fibers could
remain functional for longer; by inhibiting NOGO-A, the Type I
fibers could remain functional for a longer period decreasing the
severity of (any) motor dysfunction. By approaching the thera-
peutic intervention from the three sides of the NMJ (the motor
neuron, the muscle fiber and the TSCs), the NMJ may perhaps be
stimulated to remain in a healthy state for longer, and therefore
the onset of the disease might be more efficiently postponed than
with individual interventions. By combining this approach with
therapies like application of neurotrophic factors, one hopes to
enhance pathways that are already known to improve NMJ plas-
ticity and stability, and thus strengthen the potential benefit of the
therapeutic approach.
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